|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0045093,
umls-concept:C0069717,
umls-concept:C0205390,
umls-concept:C0235974,
umls-concept:C0574032,
umls-concept:C1512162,
umls-concept:C1521828,
umls-concept:C1707455,
umls-concept:C2603343
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2009-8-7
|
|
pubmed:abstractText |
Single-agent gemcitabine (GEM) is standard treatment of metastatic pancreatic cancer. Fixed-dose rate (FDR) GEM and GEM plus oxaliplatin have shown promise in early clinical trials. E6201 was designed to compare overall survival (OS) of standard weekly GEM 1,000 mg/m(2)/30 minutes versus GEM FDR 1,500 mg/m(2)/150 minutes or GEM 1,000 mg/m(2)/100 minutes/day 1 plus oxaliplatin 100 mg/m(2)/day 2 every 14 days (GEMOX).
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19581537,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19581537-10655437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19581537-10894879,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19581537-11595723,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19581537-12885837,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19581537-15226328,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19581537-15908661,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19581537-16258101,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19581537-16585222,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19581537-17452677,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19581537-17595663,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19581537-18772397,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19581537-5910392,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19581537-9196156
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AlbertsStevenS,
pubmed-author:BensonAl BowenAB3rd,
pubmed-author:BerlinJordanJ,
pubmed-author:CatalanoPaulP,
pubmed-author:CellaDavidD,
pubmed-author:HallerDanielD,
pubmed-author:HochsterHowardH,
pubmed-author:MitchellEdithE,
pubmed-author:O'DwyerPeterP,
pubmed-author:PoplinElizabethE,
pubmed-author:RothenbergMace LML,
pubmed-author:YangFengF
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3778-85
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19581537-Adult,
pubmed-meshheading:19581537-Aged,
pubmed-meshheading:19581537-Antimetabolites, Antineoplastic,
pubmed-meshheading:19581537-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19581537-Deoxycytidine,
pubmed-meshheading:19581537-Disease-Free Survival,
pubmed-meshheading:19581537-Drug Administration Schedule,
pubmed-meshheading:19581537-Female,
pubmed-meshheading:19581537-Humans,
pubmed-meshheading:19581537-Infusions, Intravenous,
pubmed-meshheading:19581537-Kaplan-Meier Estimate,
pubmed-meshheading:19581537-Male,
pubmed-meshheading:19581537-Middle Aged,
pubmed-meshheading:19581537-Organoplatinum Compounds,
pubmed-meshheading:19581537-Pancreatic Neoplasms,
pubmed-meshheading:19581537-Treatment Outcome,
pubmed-meshheading:19581537-United States
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
|
|
pubmed:affiliation |
Cancer Institute of New Jersey,195 Little Albany St, New Brunswick, NJ 08903, USA. poplinea@umdnj.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III,
Research Support, N.I.H., Extramural
|
